<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01069471</url>
  </required_header>
  <id_info>
    <org_study_id>SD 133</org_study_id>
    <nct_id>NCT01069471</nct_id>
  </id_info>
  <brief_title>Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella</brief_title>
  <official_title>Safety and Reactogenicity of a Candidate Vaccine Against S. Dysenteriae When Administered to Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlycoVaxyn AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlycoVaxyn AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Healthy volunteers will receive a 2-dose vaccination with Shigella dysenteriae candidate&#xD;
      vaccine spaced 8 weeks apart. The objective is to demonstrate the safety and reactogenicity&#xD;
      of the Shigella dysenteriae bioconjugate vaccine (GVXN SD133) alone or in combination with an&#xD;
      adjuvant (Aluminium Hydroxide). The safety and reactogenicity of the GVXN SD133 vaccine will&#xD;
      be also evaluated at two different concentrations of antigen, Shigella polysaccharide O1.&#xD;
      Blood samples will be collected at intervals to examine systemic vaccine antigen-specific&#xD;
      immune responses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and reactogenicity of the bioconjugate vaccine, GVXN SD133</measure>
    <time_frame>Each study visits and at the and of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Humoral immunogenicity</measure>
    <time_frame>at day 0, 30, 60, 90 and 150</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Shigellosis</condition>
  <arm_group>
    <arm_group_label>HHD O1-EPA plus adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA adjuvanted to aluminium hydroxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HHD O1-EPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LHD O1-EPA adjuvanted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA adjuvanted to aluminium hydroxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LHD O1-EPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Shigella vaccine</intervention_name>
    <description>Two intramuscular injections of bioconjugate vaccine will be administrated at D0 and D60.</description>
    <arm_group_label>HHD O1-EPA</arm_group_label>
    <arm_group_label>HHD O1-EPA plus adjuvant</arm_group_label>
    <arm_group_label>LHD O1-EPA</arm_group_label>
    <arm_group_label>LHD O1-EPA adjuvanted</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects of both sexes, aged between 18 and 50 years.&#xD;
&#xD;
          -  Subjects who have undergone a detailed medical history, clinical checkup and are in&#xD;
             good health.&#xD;
&#xD;
          -  Subjects who have understood the purpose of the study and have freely signed the&#xD;
             informed consent.&#xD;
&#xD;
          -  Subjects who consent with repeated blood samples taking.&#xD;
&#xD;
          -  Subjects who will be available to perform the follow-up visits, are reachable by&#xD;
             telephone, and are able to complete the diary cards throughout the study duration.&#xD;
&#xD;
          -  For female volunteers, a negative pregnancy test and an adequate contraception&#xD;
             throughout the study duration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history of recent contact Shigella infection or long-term residence in a&#xD;
             Shigella endemic region (Central America, Africa, and India).&#xD;
&#xD;
          -  Known history of hypersensitivity to any component of the vaccine (EPA; Aluminium&#xD;
             Hydroxide).&#xD;
&#xD;
          -  Subjects with compromised immune system.&#xD;
&#xD;
          -  Family history of congenital or hereditary immunodeficiency.&#xD;
&#xD;
          -  Chronic administration of an immunosuppressive treatment or other immune-modifying&#xD;
             drugs within six months prior to the first vaccine dose.&#xD;
&#xD;
          -  Subjects that received any other vaccine during the 1 month preceding the 1st&#xD;
             injection and may receive before the 2nd injection. If the subject needs to be&#xD;
             vaccinated during this period, he/she will be withdrawn from the study.&#xD;
&#xD;
          -  Subjects suffering of a disease at the time of enrolment. 'Disease' is defined as the&#xD;
             presence of a mild or severe illness with or without fever.&#xD;
&#xD;
          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal&#xD;
             functional abnormality, as determined by physical examination or laboratory screening&#xD;
             tests.&#xD;
&#xD;
          -  Any laboratory data collected during the screening phase found to be outside the&#xD;
             normal range defined by the laboratory.&#xD;
&#xD;
          -  Positive test for HIV, and evidence of HBV or HCV.&#xD;
&#xD;
          -  Pregnant or breast-feeding women.&#xD;
&#xD;
          -  History of alcohol, drug or psychotropic drug abuse (which interferes with a normal&#xD;
             lifestyle) during the previous year.&#xD;
&#xD;
          -  Subjects for which follow-up is compromised due to socio-cultural, geographic or&#xD;
             psychological reasons.&#xD;
&#xD;
          -  Any other significant finding that in the opinion of the Investigator that would&#xD;
             increase the risk of having an adverse outcome from participating in the study.&#xD;
&#xD;
          -  Subjects that are participating or have participated in another clinical trial in the&#xD;
             last 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Hatz, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Social and Preventive Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Social and Preventive Medicine</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>February 15, 2010</study_first_submitted>
  <study_first_submitted_qc>February 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2010</study_first_posted>
  <last_update_submitted>October 11, 2010</last_update_submitted>
  <last_update_submitted_qc>October 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Veronica Gambillara</name_title>
    <organization>GlycoVaxyn AG</organization>
  </responsible_party>
  <keyword>S.dysenteriae</keyword>
  <keyword>Healthy volunteers</keyword>
  <keyword>Conjugate vaccine</keyword>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Dose scaling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysentery, Bacillary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

